Wired

The First Crispr Medicine Is Now Approved in the US

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

PBS NewsHour

Gene therapies for sickle cell disease approved in U.S.

NPR Online News

FDA approves first gene-editing treatment for human illness

Forbes

FDA Could Approve First Crispr Treatment Today That Might Cure Sickle Cell

New York Times

F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR

FDA Approves First Crispr Treatment That Might Cure Sickle Cell

Washington Post

FDA approves two sickle cell therapies, including first CRISPR medicine

FDA approves gene-editing treatment for sickle cell disease

New sickle cell treatment sparks feelings of hope and some hesitancy among Black patients

Associated Press

Two gene therapies for sickle cell disease approved in US

FDA expected to approve first CRISPR gene-editing treatment, bringing hope to thousands with sickle cell disease

Pharmaceutical company Pfizer announced Wednesday a global recall of its sickle cell anemia drug Oxbryta, citing an "imbalance" of deaths and health complications in patients.

BNN Bloomberg

Oxbryta, which is meant to help hemoglobin attract oxygen and prevent the damaging of red blood cells, was approved by US regulators in 2019 through a fast-tracked method based only on preliminary data.

Business Wire

Pfizer said that studies had found links to deaths and Vaso-occlusive crisis in patients, adding that it's also ending all clinical trials for the drug. One study of 236 patients resulted in eight deaths among those who took Oybryta, compared to two from the placebo group.

Reuters

A day later, the European Medicines Agency suspended its approval of the drug, announcing that it was investigating 16 deaths in July and higher rates of disease complications.

Pfizer, whose stock dropped to $28.38 on Thursday, bought Oxbryta and its developer, Global Blood Therapeutics, for $5.4B in 2022, making an estimated $395M from the sickle cell drug in 2024.

Investors

The data has shown too strong of a link between Oxbryta and patient death to keep this drug on the market. While drugs are supposed to make sickle cell patients better, this one has led to additional health issues, including arthritis, kidney failure, and stroke.

Pfizer Recalls Sickle Cell Treatment Over Side Effects

The Spin

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Pfizer Recalls Sickle Cell Treatment Over Side Effects

The Spin

Articles on this story

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters